6CM
NVO

683 Capital Management’s Novo Nordisk NVO Stock Holding History

683 Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-60,000
Closed -$4.96M – 213
2024
Q4 		$5.16M Buy
+60,000
New +$6.49M 0.32% 62

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

683 Capital Management's NVO Position: Q1 2025 in Review

683 Capital Management sold out of Novo Nordisk (NVO) in Q1 2025, closing a stake of 60,000 shares — an estimated $4.96M sold.

683 Capital Management first reported a position in NVO in Q4 2024 and held it in 1 quarter. The position peaked at $5.16M in Q4 2024. 1,528 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

  • 683 Capital Management reported no remaining Novo Nordisk position as of Q1 2025 after selling out during the quarter.
  • 683 Capital Management sold 60,000 Novo Nordisk shares in Q1 2025, an estimated $4.96M.
  • 683 Capital Management first reported a position in Novo Nordisk in Q4 2024 and held it in 1 quarter.
  • 683 Capital Management's Novo Nordisk position peaked at $5.16M in Q4 2024.
  • 1,528 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on 683 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.